Arrowhead Pharmaceuticals Inc

ARWR has delivered a clear momentum breakout above the ~77 resistance on heavy volume, signaling a new expansionary phase, but price is currently stretched above rising EMAs and in extreme overbought territory. Medium-term bias remains bullish in Stage 2 with HH/HL structure intact. Execution is best deferred until a pullback into the 77–79 support zone near the 9/20 EMAs for better risk–reward.

• ↑Phase 3 plozasiran cut triglycerides 79–81% and reduced pancreatitis by 78%.
• ↑Q3 revenue reached $75M vs. $28M YoY; Redempla prescriptions doubled.
• ↓Q3 net loss widened to $194.3M vs. $175.2M YoY; opex $245M.